Medivation

Medivation, Inc.
Public (acquisition by Pfizer pending)
Traded as NASDAQ: MDVN
Industry Pharmaceutical industry
Founded 2004
Headquarters San Francisco, California, United States
Website medivation.com

Medivation is an American biopharmaceutical company focused on rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation, in collaboration with Astellas, is currently developing enzalutamide for multiple stages of prostate cancer and for breast cancer. On August 31, 2012, Medivation and Astellas announced that the U.S. Food and Drug Administration (FDA) granted approval to XTANDI® (enzalutamide) capsules for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. XTANDI is an oral, once-daily androgen receptor inhibitor.[1] Medivation is headquartered in San Francisco, California, and it began operations in December 2004 with the acquisition of Medivation Neurology, Inc.[2] The current CEO is David Hung.[3]

Pfizer announced it would acquire the company in August 2016.

Company history

2010 – Class action lawsuit

On March 3, 2010, Medivation's stock dropped $27.15 per share to close at $13.10, a 67% one-day decline on volume of 45 million shares.[4] In response, a security fraud class-action lawsuit was initiatied by Izard Nobel LLP,[5] alleging that Medivation made false and misleading statements regarding the effectiveness of Dimebon as a treatment for Alzheimer's disease, before being revealed that it did not meet primary and secondary goals in a Phase 3 trial for patients with mild to moderate Alzheimer's disease.[4]

The counsel for the case was Bernstein Liebhard and the lead plaintiffs were initially David Applestein[6][7] then Catoosa Fund, LP. On March 22, 2012, the case was dismissed with prejudice.[8] The plaintiffs appealed the dismissal in the Ninth Circuit Court of Appeals. The Ninth Circuit granted oral argument which will be held on Friday, January 17, 2014.[9] On March 7, 2014, the Ninth Circuit affirmed the dismissal of the class action, Catoosa Fund LP v. Medivation, Inc., No. 12-15960. The Ninth Circuit stated "With the exception of the tenuous and unattributed statement that Dr. Schneider relates secondhand, plaintiff has not pled any facts supporting an inference of actual knowledge by defendants. Plaintiff relies heavily on the inference that, due to their positions, the defendants must have known about the unmatched nature of the study. That inference is entirely speculative and does not rise to the required strong inference; plaintiff's allegation is not at least as compelling as any opposing inference one could draw from the facts alleged."[10]

2016

In April the company was linked with a number of potential acquirers potentially a hostile bid from Sanofi as well as links with Roche, AstraZeneca, Amgen and Gilead Sciences.[11] AstraZeneca has been reported to weigh-in with an offer of £7 billion ($10 billion).[12] On April 29, Sanofi launched a $9.3 billion takeover offer which was rejected by the Medivation board.[13] In August, Pfizer announced that it would acquire the company for $14 billion[14] or $81.50 per share, a 21% premium over the closing price on Friday August 19.[15]

Awards

EY Entrepreneur of the Year 2014 National Winner [16]

References

  1. ↑ "Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Medivation, Inc.". Law Offices of Howard G. Smith. 2010-03-03. Archived from the original on 17 November 2012. Retrieved 17 November 2012.
  2. ↑ "Investor relations". Medivation. Archived from the original on 17 November 2012. Retrieved 17 November 2012.
  3. ↑ "Management team". Medivation. Retrieved 17 November 2012.
  4. 1 2 "The Brualdi Law Firm, P.C. Announces Class Action Lawsuit Against Medivation, Inc.". New York: Bloomberg L.P. March 12, 2010. Archived from the original on 17 November 2012. Retrieved 17 November 2012.
  5. ↑ Robbins Geller Rudman & Dowd (March 9, 2010). "Class action complaint for violation of the federal securities laws". Northern District of California: Izard Nobel LLP. Archived from the original (PDF) on 17 November 2012. Retrieved 17 November 2012.
  6. ↑ "Michael S. Bigin". Bernstein Liebhard LLP. Archived from the original on 17 November 2012. Retrieved 17 November 2012. [Michael S. Bigin] represents investors in Applestein v. Medivation, Inc., No. 10-CV-00998 (EMC) (N.D. Cal.), in which plaintiffs allege that defendants inflated the price of Medivation stock by making false statements concerning the efficacy of its chief drug’s treatment of Alzheimer’s disease.
  7. ↑ "U. SETH OTTENSOSER". Bernstein Liebhard LLP. Archived from the original on 17 November 2012. Retrieved 17 November 2012. [U. Seth Ottensoser] represents investors in Applestein v. Medivation, Inc., No. 10-CV-00998 (EMC) (N.D. Cal.), in which plaintiffs allege that defendants inflated the price of Medivation stock by making false statements concerning the efficacy of its chief drug’s treatment of Alzheimer’s disease.
  8. ↑ "Medivation, Inc.". Securities class action clearinghouse. Stanford Law School. March 22, 2012. Archived from the original on 17 November 2012. Retrieved 17 November 2012.
  9. ↑ http://cdn.ca9.uscourts.gov/datastore/calendaring/2013/11/13/nsf01_14rev.pdf
  10. ↑ "Unpublished Dispositions (Memoranda)".
  11. ↑ "Sanofi could go hostile with Medivation bid".
  12. ↑ "AstraZeneca eyes Xtandi windfall with potential £7B bid for Medivation".
  13. ↑ Joshua Jamerson and Noemie Bisserbe (29 April 2016). "Medivation Rejects Sanofi's $9.3 Billion Takeover Bid". WSJ.
  14. ↑ "Pfizer to Acquire Medivation for $14B - GEN News Highlights - GEN".
  15. ↑ "Pfizer to buy cancer drug firm Medivation for $14bn". BBC News.
  16. ↑ Medivation. "Medivation CEO David Hung Named National EY Entrepreneur Of The Year 2014 Overall Award Winner." Medivation.com. Medivation, 17 Dec. 2014. Web. <http://investors.medivation.com/releasedetail.cfm?ReleaseID=883449>.
This article is issued from Wikipedia - version of the 10/10/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.